Find Funding Opportunities

The purpose of the Academic Research Enhancement Award (AREA) program is to stimulate research in educational institutions that provide baccalaureate or advanced degrees for a significant number of the Nation's research scientists, but that have not been major recipients of NIH support. AREA grants create opportunities for scientists and institutions otherwise unlikely to participate extensively in NIH research programs to contribute to the Nation's biomedical and behavioral research effort. AREA grants are intended to support small-scale research projects proposed by faculty members of eligible, domestic institutions, to expose undergraduate and/or graduate students to meritorious research projects, and to strengthen the research environment of the applicant institution.

This Funding Opportunity Announcement (FOA) is intended to address the problem of misidentified cell lines. Many advances in biomedical science have arisen from studies of cultured cell lines, which are widely used for basic research on cell function, as models for disease, and for drug screening. However, cell cultures are prone to contamination by foreign cells, which may rapidly displace the original cells. The identity of cultured cells should be routinely verified, but a majority of laboratories do not monitor the identity of their cell lines, and many cell lines are misidentified. The costs, effort and time required to confirm the identity of cell lines has been a barrier to adoption of cell line identification as a routine quality control measure. This FOA will support SBIR projects to improve existing technologies, and/or develop novel, reliable, and cost effective tools that will make it easier for researchers to confirm the identity and/or sex of the cells that they use in their work. Applications for support of research and development of particular types of complex technologies that require funding levels and durations beyond those reflected in standard SBIR guidelines are encouraged, as are multi-PD/PI applications, including multi-PD/PI applications that arise from academic-industrial partnerships.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and protected time to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research. Individuals with a clinical doctoral degree interested in pursuing a career in patient-oriented research should refer to the NIH Mentored Patient-Oriented Research Career Development Award (Parent K23). Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The purpose of the NIH Independent Scientist Award (K02) is to foster the development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. The K02 award provides three, four, or five years of salary support and protected time for newly independent (see IC provisions) scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers. Each independent scientist career award program must be tailored to meet the individual needs of the candidate. Prospective candidates are encouraged to contact the relevant Institute or Center (IC) staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The purpose of the NIH Pathway to Independence Award (K99/R00) program is to increase and maintain a strong cohort of new and talented, NIH-supported, independent investigators. This program is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NIH research support during this transition in order to help awardees to launch competitive, independent research careers. Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts.

The purpose of the NIH Mentored Patient-Oriented Research Career Development Award (K23) is to support the career development of individuals with a clinical doctoral degree who have made a commitment to focus their research endeavors on patient-oriented research. Individuals with a clinical degree who are interested in further career development in biomedical research other than patient-oriented research should refer to the Mentored Clinical Scientist Career Development (Parent K08) Award. Prospective candidates are encouraged to contact the relevant NIH staff for IC-specific programmatic and budgetary information: Table of IC-Specific Information, Requirements and Staff Contacts

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

The purpose of this Funding Opportunity Announcement (FOA) is to inform the scientific community of the pain research interests of the various Institutes and Centers (ICs) at the National Institutes of Health (NIH) and to stimulate and foster a wide range of basic, clinical, and translational studies on pain as they relate to the missions of these ICs. New advances are needed in every area of pain research, from the micro perspective of molecular sciences to the macro perspective of behavioral and social sciences. Although great strides have been made in some areas, such as the identification of neural pathways of pain, the experience of pain and the challenge of treatment have remained uniquely individual and unsolved. Furthermore, our understanding of how and why individuals transition to a chronic pain state after an acute injury is limited. Research to address these issues conducted by interdisciplinary and multidisciplinary research teams is strongly encouraged, as is research from underrepresented, minority, disabled, or women investigators.

This funding opportunity is intended to provide support through an administrative supplement to existing Rare Diseases Clinical Research Network (RDCRN) awardees whose projects encompass the implementation of clinical trials. Through this supplement, NCATS intends to provide support for phase 1 and/or 2 clinical trial sites that will test the potential use of an existing molecule for the treatment of a rare disease as part of a multi-site international E-Rare-3 trial.

This funding opportunity announcement invites research grant applications focused on: identifying HIV-1-infected cells in the central nervous system (CNS) compartment that are latently infected; developing strategies for targeting these latently infected cells; and aiming to achieve viral silencing leading to inhibition of viral production, without the need for pro-viral reactivation.